Abstract An increase in dermatan sulfate-proteoglycan (DSPG) production occurs in cultured aortic smooth muscle cells exposed to macrophage-conditioned media, an effect that is abrogated by an antibody to interleukin-1 (IL-1). To determine which DSPG gene was regulated, cultured arterial smooth muscle cells from monkeys (Macaca fascicularis) were treated with 0 to 500 pg/mL human recombinant IL-la or IL-1/3 in the presence of [ 35
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Abstract An increase in dermatan sulfate-proteoglycan (DSPG) production occurs in cultured aortic smooth muscle cells exposed to macrophage-conditioned media, an effect that is abrogated by an antibody to interleukin-1 (IL-1). To determine which DSPG gene was regulated, cultured arterial smooth muscle cells from monkeys (Macaca fascicularis) were treated with 0 to 500 pg/mL human recombinant IL-la or IL-1/3 in the presence of [ Proteoglycans were isolated from the culture media and purified by selective precipitation and chromatography. Both recombinant IL-la and IL-10 caused a dose-response increase in DSPG production. Northern blot analysis of mRNA isolated from the cells identified 1.6-kb and 2.6-kb P roteoglycans (PGs) are a family of complex macromolecules composed of glycosaminoglycan (GAG) chains of repeating disaccharides covalently linked to a core protein. The disaccharide composition of the GAG chains defines the different PG types, and the core protein sequence defines the genetic product and specific PGs. A chondroitin sulfate (CS)-containing PG similar to versican is the predominant PG in artery, with dermatan sulfate (DS) PG the second major class (see Reference 1 for review).
Two distinct DSPG molecules, biglycan and decorin, have been identified in a number of tissues including cartilage, 2 -3 bone, 4 " 6 skin, 3 and artery. 7 Biglycan from calf articular cartilage and bovine fetal skin each possess two DS chains and have, respectively, average molecular masses of 150 kD and 148 kD as measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Decorin, which possesses only one DS chain, has an average molecular mass of 101 kD in cartilage and 103 kD in skin.
2 -3 cDNA sequences predict molecular weights of 36 and 38 kD, respectively, for human bone decorin and biglycan core protein. Both proteins contain highly homologous leucine-rich regions but distinct amino-tenninus sequences. 35 Decorin may function to regulate collagen fibrillogenesis 8 and to regulate cell proliferation by interaction with transforming growth factor type-/3 (TGF-/3). 9 The function of A consistently reported change in arterial PGs during the progression of atherosclerosis is an increase in DSPGs. 1012 Whether this represents increased decorin or biglycan is not known. Also unclear is the reason for the accumulation of DSPGs. Arterial PGs are produced by smooth muscle cells, which in some cases are exposed to macrophage secretory products very early in the development of atherosclerosis. Macrophage products such as TGF-/3, 1322 platelet-derived growth factor (PDGF), 2122 and interleukin-1 (IL-1) 2332 modulate the synthesis of PGs by various cell types. When cultured arterial smooth muscle cells are exposed to macrophage-conditioned media, DSPG production is enhanced twofold to fivefold. 33 An anti-IL-1 antibody totally abolishes the effect, suggesting that IL-1 is the macrophage product responsible for the DSPG enhancement. 33 The present studies were conducted using human recombinant IL-1 to assess more directly the effects of IL-1 at several dose levels and to determine whether the enhanced DSPG production was due to upregulation of decorin or biglycan.
Methods Materials
Human recombinant IL-1/3 was a generous gift from Dr Robert C. Newton, Du Pont-Merck Pharmaceutical Co, and human recombinant IL-la was purchased from Genzyme Corp. Anti-peptide antibodies to decorin (LF-30) and biglycan (LF-51) and cDNA for the full-length core protein of human bone decorin (P2) and biglycan (P16) 3 were generously provided by Dr Larry Fisher of the Bone Research Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, Md. Tissue culture reagents were purchased from JRH Biosciences and calf serum from ICN Biomedicals. [ M S]Sodium sulfate (600 to 900 Ci/mmol) was purchased from Amersham Corp, ENLIGHTNING and [o-^PJdCTP were from Du Pont-New England Nuclear, and L-serine [G-to 25 Ci/mmol) was from ICN. Ultrapure guanidine hydrochloride (GdnHCl) and urea were from ICN, Triton X-100 was from Pierce Chemical Co, and Kodak X-Omat AR x-ray film was from Eastman. 1-Hexadecylpyridinium chloride (CPC) (Eastman) was twice purified by recrystallization with acetone. Phenylmethylsulfonyl fluoride and pepstatin were obtained from Sigma; CS was from Nutritional Biochemicals Corp; chondroitin ABC lyase (Proteus vulgaris) and chondroitin AC lyase (Arthrobacter aurescens) were from Seikagaku America, Inc; READY SAFE liquid scintillation cocktail was from Beckman Instruments; mRNA purification kits were from Stratagene; Zeta-Probe, polyvinylidene difluoride (PVDF), nitrocellulose membranes, and all PAGE reagents were from Bio-Rad. Herring sperm DNA was from Promega. All other reagents were from Fisher. Plasticware was from Marsh Biomedical or Fisher.
Cell Culture
Smooth muscle cells were isolated from the thoracic aortas of adult monkeys (Macaca fascicularis) as described. 34135 They were subcultured in 75-cm 2 T-flasks in 20 mL Eagle's minimal essential medium with Earle's base salts supplemented with 100 U/mL penicillin, 100 jig/mL streptomycin sulfate, 200 mmol/L L-glutamine, and 10% heat-inactivated newborn calf serum. Cells from the fourth to eighth passage were plated either in 35-mm dishes in 2 mL medium and used for PG analysis or in 100-mm dishes in 10 mL medium and used for RNA isolation.
IL-1 Treatment and Radiolabeling of PGs
To assess the effect of IL-1, the media from confluent (5-day) cultures were removed and replaced with media containing various concentrations of human recombinant IL-la or IL-1/3. Unless otherwise indicated, cells were grown and IL-1 treatments were performed in media containing 10% newborn calf serum. To radiolabel the PGs, the treatment media also contained 30 /iCi [/"SJsodium sulfate per milliliter and 30 |/,Ci [ 
PG Isolation
Following a 36-hour treatment, the radiolabeling media were removed and cleared of cell debris by centrifugation at 450g for 10 minutes. Media were exhaustively dialyzed against 0.03 mol/L Na 2 SO 4 and 0.02 mol/L NaCl at 4°C to remove unincorporated radiolabel before identification of PGs. The cell layer was trypsinized as described, 36 and cell numbers were determined by hemocytometer counts. Trypsin fluidswere used for purification of cell surface and pericellular PGs. Both media and cell surface PGs were precipitated in the presence of 100 jtg added carrier CS for 48 hours at 25°C by using 1% CPC as described. 33 The complexes were dissolved in phosphate-buffered saline (13.7 mmol/L NaCl, 2.7 mmol/L KC1,1.5 mmol/L KH 2 PO 4 , and 8.1 mmol/L Na 2 HPO 4 , pH 7.4) and analyzed for radioactivity.
PG Identification by Enzymatic and Chemical Degradation
Aiiquots of PGs were treated for 16 hours at 37°C with 0.05 U of either chondroitinase ABC (pH 8.0) or chondroitin AC II lyase (pH 7.4) in 0.03 mol/L sodium acetate and 0.1 mol/L tris(hydroxymethyl)aminomethane (Tris) containing protease inhibitors. 37 To identify heparan sulfate (HS) PGs, aiiquots of radiolabeled PGs were incubated for 2 hours at 25°C with an equal volume of 20% butyl nitrite/lN HC1 followed by neutralization with IN NaOH.
Size Exclusion Chromatography
Aiiquots of intact, enzymatically or chemically treated PGs were diluted in 0.25 mol/L Tris phosphate, pH 7.6, and chromatographed on a high-performance liquid chromatography (HPLC) Altex Spherogel TSK 5000 PW column (300x7.5 mm) at a flow rate of 0.5 mL/min using 0.25 mol/L Tris phosphate, pH 7.6, as the elution buffer. Fractions (0.5 mL) were collected, and radioactivity was measured by liquid scintillation counting. Movement of M S radioactivity to a position indicative of lower molecular weight (column V,) was used to indicate degradation of the GAG chains.
PAGE and Western Immunoblotting
Intact PGs or PG core proteins prepared by chondroitinase ABC treatment were adjusted to 0.05 mol/L Tris, pH 8.0, 1% SDS, and 1% ^-mercaptoethanol and boiled for 2 minutes. Samples were separated by electrophoresis on a 3% to 12% polyacrylamide gel by the method of Laemmli 38 using protein standards as molecular-weight markers. The gel was fixed, treated with ENHANCE, and dried, and the radioactive bands were visualized by autoradiography. For immunoblotting, PGs and PG core proteins separated on a 3% to 12% gradient gel were transferred to PVDF membranes using a Bio-Rad transblot apparatus according to the manufacturer's directions. After blocking with Tris-buffered saline (TBS) containing 5% bovine serum albumin (BSA) and 0.5% powdered milk, the membranes were washed with TBS and incubated for 2 hours at 25°C with monoclonal antibodies LF-51 (for biglycan) and LF-30 (for decorin) diluted 1:50 in TBS containing 0.5% BSA and 0.5% powdered milk. Immunoreactive bands were visualized as positive for peroxidase by using a horseradish peroxidase-conjugated second antibody as described.
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RNA Extraction and Northern Blot Analyses
Total RNA was isolated from cell cultures by using a Stratagene RNA isolation kit according to the manufacturer's directions. The ratio of optical density at 260 to 280 nm of the RNA was greater than 1.9 for all preparations. RNA was fractionated by electrophoresis at 60 to 100 V for 16 hours on 1% agarose gels containing 2.2 mol/L formaldehyde and then transferred to nitrocellulose membranes and immobilized by exposure to UV light to create covalent bonds. The membranes were then baked at 80°C in a vacuum oven for 1 hour before prehybridization for 2 hours at 52°C in 6x salinesodium citrate (SSC) (lx SSC equals 0.15 mmol/L NaCl and 0.015 mol/L sodium citrate) and 2x Denhardt's solution (0.2 g Ficoll 400, 0.2 g polyvinylpyrrolidone, 0.2 g BSA, and 0.1% SDS). cDNA probes were labeled by random priming with [a-3 P]dCTP using a kit from Boehringer Mannheim Corp and were hybridized to the transferred RNA at 52°C for 16 hours in the above buffer containing 100 /ig/mL herring sperm DNA. The membranes were then washed three times in 2x SSC, twice in l x SSC, and twice in 0.5x SSC. All SSC solutions contained 0.1% SDS, and each wash was at 26°C for 30 minutes. After washing, the membranes were air-dried and subjected to autoradiography by exposure to Kodak X-Omat AR x-ray film for 16 hours at -70°C.
Slot-Blot Analyses
RNA was added to prewetted Zeta-Probe membranes using a Bio-Dot SF apparatus (Bio-Rad) according to the manufacturer's instructions. Membranes were gently rinsed with 2x SSC, and the RNA was immobilized by UV light exposure. After baking the membrane at 80°C for 1 hour, hybridization with ^P-labeled cDNA probes was performed as described for Northern blot analyses, except that the buffer used was 0.25 mol/L Na 2 HPO 4 , pH 7.2, containing 0.25 mol/L NaCl, 50% formamide, 7% SDS, and 1 mmol/L EDTA, and the hybridization temperature was 43°C. Radioactive bands were measured using a radioanah/tical imaging system (Ambis Systems). In some experiments, autoradiographs were prepared from the slot blots and scanned using an Ultrascan XL laser scanner (LKB) at 633 nm. Areas under densitometric peaks were integrated, and values were corrected by normalization to glyceraldehyde-3 -phosphate dehydrogenase mRNA.
Radioactivity Measurements on Liquid Samples
35
S and 3 H radioactivity measurements were made in a Packard 1500 Tri-Carb scintillation counter with READY SAFE as the fluor.
Results
To determine the effect of human recombinant IL-1 on PG synthesis by monkey arterial smooth muscle cells, varying doses of IL-la or IL-ljS were added to confluent cell cultures in the presence of [ 35 S]sodium sulfate. PG synthesis was assessed by incorporation of [ 35 S]sulfate into nondialyzable, CPC-precipitable macromolecules. Over a 36-hour labeling period, in all treatments, 89% to 91% of the newly synthesized PGs was secreted into the culture media, leaving approximately 10% associated with the cell surface and removable with trypsin (pericellular PGs). This fraction contained HSPGs and CSPGs but no detectable decorin or biglycan (data not shown). As shown in Fig 1, at concentrations above 5 pg/mL, there was a concentration-dependent increase in PGs produced and released into the media following treatment with either IL-la or IL-1/3. Because of the long labeling period, these data represent both synthesis and turnover of PGs.
Identification of Stimulated PGs
To determine if IL-1 treatment resulted in enhanced production of a specific PG type, radioactive PGs were isolated from the culture media of control and IL-1/3-treated samples and identified by susceptibility to specific GAG degrading enzymes or nitrous acid. Products were analyzed by HPLC size exclusion separation in which movement of [ 35 S]sulfate to the column V, indicated hydrolysis of the GAG chains to disaccharides (Fig 2) . Intact PGs from both control (Fig 2A) and IL-1-treated (Fig 2B) samples eluted in a broad peak between the column V o and a K^ of approximately 0.4. Chondroitinase ABC treatment resulted in movement of the majority (87% to 92%) of radiolabel to the column V, (Fig 2, C and D) , indicating that the secreted PGs produced by Macaca fascicularis smooth muscle cells consist predominantly of CSPGs and DSPGs. Treatment with nitrous acid following treatment with chondroitinase ABC resulted in hydrolysis of all remaining ^S-labeled chains, indicating that the remaining 8% to 13% of sulfated PGs were HSPGs (data not shown). The enzyme chondroitinase AC II will not cleave iduronosyl linkages of DS chains and therefore can be used to distinguish between DSPGs and CSPGs. Treatment with this enzyme resulted in fragments of DSPGs, which remained in the column (Fig 2, E and F) . In IL-1/3-treated cells (Fig 2F) , this fraction was increased relative to V, material, indicating enhanced production of DSPGs by IL-1.
PG Core Protein Analysis
An increase in DSPGs in response to IL-1 was confirmed by examination of the PG core proteins. In this experiment, PGs were isolated from cells that had been radiolabeled with both [ M S]sulfate and pHJserine during IL-1/9 treatment. Intact PGs and core proteins generated by chondroitinase ABC treatment were separated by SDS-PAGE and subjected to autoradiography (Fig 3) . When chondroitinase ABC was used to generate core proteins of CSPGs and DSPGs, an increase in the 45-kD core proteins of DSPGs was observed in PGs from IL-1-treated cells (Fig 3A, lane 4) . Densitometric scans of the autoradiogram indicated that the area under the 45-kD core protein peak increased from 16% of total in the control to 26% in the sample from IL-1-treated cells. Since both decorin and biglycan have chondroitinase ABC-generated core proteins of approximately 45 kD, the two PGs were distinguished by immunoblotting using peptide-specific antibodies to decorin and biglycan (Fig 3B) . The core protein of decorin was identified in PGs isolated from both control and IL-1-treated samples (Fig 3B, lanes 1 and 2) . Ambis radioanalytical imaging system analysis of the radioactivity associated with the anti-decorin reactive bands indicated a 35% increase in 3 H incorporation in the sample from IL-1-treated cells. The anti-biglycan antibody showed little detectable immunoreactivity with either sample (Fig 3B, lanes 3 and 4) , indicating that under the conditions of these experiments Macaca fascicularis smooth muscle cells produce primarily decorin with relatively little biglycan. These data are consistent with those of Carlson et al, 40 who used the LF-51 antibody to examine biglycan distribution in Macaca fascicularis tissue. They reported immunostaining in articular cartilage and adventitia of blood vessels but not around medial smooth muscle cells of blood vessels.
Effect of IL-1/3 on the Expression of mRNA Transcripts for Biglycan and Decorin in Monkey Arterial Smooth Muscle Cells
To determine the presence of mRNAs encoding core proteins of decorin and biglycan in Macaca fascicularis S-radiolabeled proteogfycans (PGs) treated enzymatically to identify PG type. PGs produced by monkey arterial smooth musde cells in the absence (A, C, and E) or presence (B, D, and F) of 500 pg/mL human recombinant irrterleukin-1 p were isolated from the culture medium by 1-nexadecyipyridinium chloride precipitation. They were treated with either ctiondroitinase ABC or chondroitinase AC II for 16 hours at 37°C and chromatographed on a TSK PW 5000 high-performance liquid chromatography column using 0.25 mol/L tris(hydroxymethyf)aminom ethane-phosphate, pH 7.6, as the mobile phase. Fractions (0.25 mL) were collected and analyzed for radioactivity. A and B, Intact PGs; C and D, chondroitinase ABCtreated PGs; E and F, chondroitinase AC IMreated PCs.
Vo arterial smooth muscle cells, total cellular RNA was isolated and examined by Northern hybridization. Fulllength cDNA probes for biglycan and decorin hybridized to 2.6-kb and 1.6-kb transcripts, respectively (Fig  4) . These sizes correspond to the reported transcript size for each molecule in human tissues.
Using the cDNA probes for decorin and biglycan, the effect of IL-1 on expression of the decorin and biglycan genes was examined. Cells were treated with varying doses of IL-1/3 for 36 hours before isolation of total cell RNA. The RNA was used in a slot-blot analysis from which an autoradiogram was prepared and mRNA quantified. IL-1 caused a dose-response increase in decorin mRNA (Fig 5) . After exposure of the cells to 500 pg/mL IL-1, decorin gene expression was increased 82% over untreated cells. By contrast, expression of the biglycan gene was not increased at any level of IL-1 treatment (data not shown). These results were confirmed in additional experiments in which increases of up to 200% in steady-state levels of decorin mRNA were measured in cells treated with 500 pg IL-1)3 (Table). No increases in biglycan mRNA were observed.
Effect of Serum on IL-1 Regulation of PG Genes
Since PG synthesis is known to be regulated by several serum components, such as TGF-/3 1322 and PDGF, 21 confluency in medium containing 10% serum. This was replaced with media containing 0.1%, 2.0%, 5.0%, or 10.0% serum with or without 500 pg/mL IL-1 for 36 hours before isolation of RNA. Fig 6 depicts a slot-blot analysis in which "P-labeled probes for decorin and biglycan were employed to quantify message levels using an Ambis radioactivity detector. In the absence of IL-1, the decorin gene expression was slightly higher at low serum concentrations relative to a more physiological concentration of 10% (Fig 6, left) . When IL-1 was present, a marked increase in decorin mRNA was observed at both 5% and 10% serum. By contrast, neither serum concentration nor IL-1 had any significant effect on biglycan gene expression (Fig 6, right) .
Discussion
These studies have demonstrated that human recombinant IL-10 stimulates production of the DSPG decorin in monkey arterial smooth muscle cells. Upregulation of decorin in IL-1-treated cells was measured as enhanced levels of mRNA as well as increased decorin product, indicating that IL-1 induced upregulation of decorin gene expression. The effect was specific for decorin, since message levels for the other DSPG, biglycan, were not enhanced by IL-1 treatment.
The effect of IL-1 on decorin and biglycan was studied at several different serum levels, since many reports show that serum components influence PG synthesis. In fibroblasts, TGF-/3 upregulates versican and biglycan but downregulates decorin. 1718 In smooth muscle cells, both TGF-/3 and PDGF stimulate the production of versican and biglycan with little effect on decorin.
21 ' 22 In the present studies, IL-1 stimulation of decorin mRNA was observed only when medium serum concentrations were over 5%, suggesting a synergism between IL-1 and presently unidentified serum components. Further studies are required to demonstrate whether the effect of IL-1 on PG synthesis is direct or indirect and which specific serum components may be involved.
IL-1 has mitogenic activity in fibroblasts 4142 and in smooth muscle cells cultured in media that are made deficient in platelet products by the use of plasmaderived serum. 43 Under those conditions, an indirect mitogenic effect of IL-1 on the cells is due to enhanced production of PDGF-AA. 43 In the present studies smooth muscle cell proliferation was not stimulated by IL-1 at any serum level. Similar observations are reported by Libby et al,
42
-44 who show that IL-1 stimulates smooth muscle cell production of growth-inhibitory eicosanoids, which block a mitogenic response. In the presence of cyclooxygenase inhibitors to block eicosanoid production, a mitogenic response to IL-1 could be demonstrated. Total RNA isolated from confluent cultures of monkey aortic smooth muscle cells was separated by electrophoresis on 1% agarose-formaldehyde gels and transferred to nitrocellulose membranes. Message for decorin and biglycan was detected by hybridization with "P-labeled cDNA probes for human decorin and biglycan. These probes hybridized to a 2.6-kbp message for biglycan and a 1.6-kbp message for decorin. The positions of 18S and 28S ribosomal RNA markers were determined by ethldium bromide staining.
types. 45 A number of studies have emphasized a role for IL-1 in the pathogenesis of atherosclerosis. IL-10 mRNA has been identified in atherosclerotic tissue of both monkeys 46 ' 47 and rabbits, 48 and cultured arterial endothelial cells and smooth muscle cells have been identified as both a source and a target for IL-1.
49 -
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These studies describe potential amplification loops in which exogenous IL-1 stimulates the production of IL-1 by arterial endothelial cells and smooth muscle cells, thus increasing the availability of IL-1 in the arterial wall. Vascular effects induced by IL-1 include increased permeability to plasma components (see Reference 51 for review). This process may involve alterations in both endothelial cell and smooth muscle cell metabolism, with modulation of the extracellular matrix produced by smooth muscle cells as a major factor. In addition to the present report of increased decorin gene expression by IL-1, previous studies suggest IL-1-induced degradation of a CSPG core protein. 33 In cartilage, IL-1 stimulates the production of proteases and is an important mediator of tissue loss by both inhibition of PG synthesis and stimulation of PG breakDown.
29
- 32 CSPGs from IL-1-treated cultured chondrocytes have a reduced capacity for interaction with hyaluronic acid. 27 Although similar processes in the artery wall have yet to be demonstrated, this is a potentially important mechanism that would impair the passage-restriction function of PG-hyaluronic acid aggregates.
One hallmark of advanced atherosclerotic lesions is fibrosis. IL-1 enhances the expression of collagen types In media containing 10% newborn calf serum. Total cell RNA was isolated and, using ^P-labeled cDNA probes, decorin mRNA was measured by slot-blot hybridization and autoradiography. Insert, Autoradiograms of slot blot of mRNA for glyceraldehyde-3-phosphate dehydrogenase (upper) and decorin (lower). Autoradiograms were scanned by a laser densitometer. Data are based on areas under the peaks of densitometric scans corrected for glyceraldehyde-3-phosphate dehydrogenase and are expressed as percent above control for message levels of decorin at varying concentrations of IL-1 p. Northern analysis was used to confirm that in mRNA from cells treated with 500 pg/mL IL-1/3, only the appropriate transcript was recognized (data not shown).
I and III in human vascular smooth muscle cells. 52 The present observations of IL-1 stimulation of decorin provide further evidence of the capacity of IL-1 for modulation of extracellular matrix components involved in fibrotic processes. One important property of decorin is its ability to bind types I and II collagen and to regulate the size or organization of collagen fibrils. Whereas decorin from skin 53 or tendon 8 delayed fibrillogenesis in an in vitro assay, decorin from aorta had no effect on the rate of fibrillogenesis but induced an increase in the amount of collagen fibril formation. 8 Increased decorin in the artery wall may therefore be ah important factor in the fibrosis associated with the progression of atherosclerosis. IL indicates interieukin. Cells were treated for 36 hours with 500 pg/mL IL-1/3 in media containing 10% newborn calf serum. Total RNA was isolated, and slot blots were prepared usinĝ P-labeled probes for decorin and biglycan. In experiment 1, autoradiograms of the blots were scanned by laser densitometer, and data are based on areas under the peaks of densitometric scans. In experiment 2, radioactivity of slot blots was measured by Ambis radioanalytical imaging system. Glyceraldehyde-3-phosphate dehydrogenase mRNA was used for normalization of the data in both experiments. were treated for 36 hours with 0 or 500 pg/mL IL-1/3 in media containing different serum concentrations. Total cell RNA was isolated, and using ^P-labeled cDNA probes, mRNA for decorin and biglycan was measured by slot-blot hybridization followed by quantification of radioactivity using an Ambis radioanalytical imaging system. Data were normalized by comparison to glyceraldehyde-3-phosphate dehydrogenase without IL-1 (hatched bars) or with IL-1 (crosshatched bars).
A second characteristic of the fibrotic lesion is smooth muscle cell proliferation. This may be regulated by a complicated interaction of stimulatory growth factors such as PDGF and basic fibroblast growth factor and inhibitory factors such as TGF-/3. Decorin binds TGF-0 and modulates its activity. 9 In Chinese hamster ovary cells, which respond to TGF-/3 by growth stimulation, TGF-)3 was active only when released from decorin, and the presence of decorin inhibited growth. In MvlLu cells, which respond to TGF-0 by growth inhibition, the presence of decorin reversed that effect. TGF-/3 inhibits the growth of aortic smooth muscle cells 54 ; therefore, one can propose that if increased decorin sequesters TGF-/3 and thus its activity in the artery, the result would be increased cell proliferation.
The studies in this report indicate a differential regulation of individual PGs by IL-1 with preferential enhancement of decorin. These in vitro observations suggest a mechanism to explain the reported increases in DSPGs during progression of atherosclerosis 1012 and processes leading to advanced fibroproliferatrve plaques.
